E
Sell
11/27/2023Downgrade
MustGrow Biologics Corp. (MGROF) was downgraded to E+ from D- on 11/27/2023 due to a major decline in the solvency index, total return index and growth index. Debt to equity increased from 0.18 to 0.23, operating cash flow declined 21.43% from -$674.6 to -$819.2, and the quick ratio declined from 3.74 to 3.09.
D
Sell
3/14/2023Downgrade
MustGrow Biologics Corp. (MGROF) was downgraded to D- from D on 03/14/2023.
D
Sell
2/23/2023Upgraded
MustGrow Biologics Corp. (MGROF) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index, volatility index and valuation index.
D
Sell
2/8/2023Downgrade
MustGrow Biologics Corp. (MGROF) was downgraded to D- from D on 2/8/2023 due to a noticeable decline in the growth index, total return index and solvency index. Total revenue declined 65.52% from $2.9 to $1, EBIT declined 60.81% from -$997.1 to -$1.6M, and earnings per share declined from -$0.0226 to -$0.0332.
D
Sell
5/16/2022Upgraded
MustGrow Biologics Corp. (MGROF) was upgraded to D from D- on 5/16/2022 due to an increase in the volatility index and valuation index.
D
Sell
5/1/2022Downgrade
MustGrow Biologics Corp. (MGROF) was downgraded to D- from D on 5/1/2022 due to a decline in the growth index and volatility index. Total revenue declined 100% from $10.2 to $0, EBIT declined 59.5% from -$488.6 to -$779.3, and operating cash flow declined 49.76% from -$391.7 to -$586.6.
D
Sell
4/21/2022Upgraded
MustGrow Biologics Corp. (MGROF) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
MustGrow Biologics Corp. (MGROF) was downgraded to E+ from D on 4/20/2022 due to a significant decline in the total return index and valuation index.
D
Sell
11/9/2021Upgraded
MustGrow Biologics Corp. (MGROF) was upgraded to D from E+ on 11/9/2021 due to an increase in the total return index and valuation index.
E
Sell
11/8/2021Downgrade
MustGrow Biologics Corp. (MGROF) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index, growth index and solvency index. Debt to equity increased from 0.32 to 0.42, EBIT declined 16.87% from -$418.4 to -$489, and the quick ratio declined from 5.55 to 4.85.
